Coloplast A/S (OTCMKTS: CLPBY), a Danish company, witnessed a substantial increase in the number of short positions taken during November. As of November 15th, the total number of shares borrowed to cover short positions increased to 81,900 from 900 the day before. The current short-interest ratio is 0.3 days, with an average trading volume of 234,700 shares. This is because there are now short positions available.
During the middle of the trading day on Monday, OTCMKTS CLPBY climbed $0.19 to $12.23. There were 113,280 outstanding shares, and the stock was trading at 32,600 shares. The moving average for the company over the past 50 days is $10.96, and the moving average over the past 200 days is $11.33. The debt-to-equity ratio comes in at 0.02, the quick ratio clocks in at 0.90, and the current ratio sits at 1.29. The price-to-earnings ratio for the company is 40.77, and it has a beta value of 0.28. The market capitalization of the company is $26.42 billion. Coloplast A/S hit a low of $9.58 over the past year while reaching a high of $17.99 over the same period.
Recent reports from several analysts have focused on CLPBY as their primary topic. The “buy” rating that Jefferies Financial Group had previously assigned to Coloplast A/S was changed to a “hold” rating in a research note published on Tuesday, September 20th. Barclays increased their price target on Coloplast A/S shares from 780.00 to 835.00 and gave the stock an “underweight” rating in a report released on Tuesday, November 22nd. Credit Suisse Group lowered their price target on Coloplast A/S shares in a report published on Wednesday, November 9th. The new price target is $1,045.00, down from $1,100.00. Finally, Morgan Stanley initiated coverage of Coloplast A/S shares in a research report issued on Tuesday, October 18th. They rated the stock as “overweight,” meaning it has a positive outlook.
Last but not least, in a research note released on Tuesday, November 8th, UBS Group lowered their price objective on shares of Coloplast A/S from $878.00 to $840.00. There has been one analyst who has suggested that the stock be sold, three analysts who have suggested that it be kept, and two analysts who have suggested that it be purchased. According to the data from Bloomberg, the firm is presently rated with an average of “Hold,” and the price objective has been set at $925.00.
In Denmark, the United States of America, the United Kingdom, and France, as well as other countries, the company Coloplast A/S produces and sells goods and services related to intimate healthcare. Chronic care, interventional urology, and wound and skin care make up the organization’s three different departments. Under the Brava brand, the company distributes ostomy care devices such as the SenSura Mio, which conforms to different body types and offers the highest level of discretion for a variety of ostomies, as well as SenSura Ostomy Care Solutions and Ostomy Accessories.
Read More: Coloplast A/S (OTCMKTS:CLPBY) short interest rises by 9,000.0%.